The need to keep vaccines in a 2°C to 8°C cold chain is a constraining factor for many immunization campaigns due to limited storage capacity and/or limited ice pack freezing capacity; supplementary immunization activities planned across sub-Saharan Africa to introduce MenAfriVac™ are a good example. In 2012, the licence for the Serum Institute of India’s meningitis A vaccine, MenAfriVac®, was changed based on a thorough review of scientific data by regulatory authorities and the World Health Organization (WHO) to allow for the use of the vaccine for a period of up to 4 days at temperatures of up to 40°C in a controlled temperature chain (CTC).
WHO has published three documents to provide support on use and adoption of CTC:
1. This document gives guidance on how to use the CTC: Use of MenAfriVac (meningitis A vaccine) in a controlled temperature chain (CTC) during campaigns Use of MenAfriVac (meningitis A vaccine) in a controlled temperature chain (CTC) during campaigns
2. A training module that teaches how to integrate the CTC into your routine immunization programme:
Training module for organizing immunization sessions
3. This document tells countries how to adapt the generic training module to the local situation: Adaptation guide and facilitator's guide
There are no replies made for this post yet.
Please login to post a reply
You will need to be logged in to be able to post a reply. Login using the form on the right or register an account if you are new here. Register Here »